The discordance rate of the estimated PD-L1 score between specimens from different tumour sites highlights the difficulty of representing PD-L1 status with a single test value and is relevant for clinical decision-making when anti-PD-L1/PD-1 blocking agents are a treatment option. Here, CD274 is linked to neoplasm.